4.83
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes - GlobeNewswire
GlobeNewswire
Capricor's cell therapy shows three year benefit in DMD patients - Clinical Trials Arena
Clinical Trials Arena
Capricor's cell therapy shows three year benefit in DMD patients - Yahoo Finance
Yahoo Finance
What's Going On With Capricor Therapeutics Stock Friday? - Capricor Therapeutics (NASDAQ:CAPR) - Benzinga
Benzinga
Capricor Therapeutics Rises on Muscular Dystrophy Treatment Study - MarketWatch
MarketWatch
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac ... - GlobeNewswire
GlobeNewswire
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac ... - WICZ
WICZ
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac ... - Yahoo Finance
Yahoo Finance
Strength Seen in Capricor (CAPR): Can Its 5.7% Jump Turn into More Strength? - Yahoo Movies UK
Yahoo Movies UK
Slated Capricor, FDA meeting to focus on DMD therapy deramiocel - Muscular Dystrophy News
Muscular Dystrophy News
Slated Capricor, FDA meeting to focus on DMD therapy deramiocel - Muscular Dystrophy News
Muscular Dystrophy News
FDA sets meeting for Capricor's DMD treatment application By Investing.com - Investing.com
Investing.com
FDA sets meeting for Capricor's DMD treatment application By Investing.com - Investing.com UK
Investing.com UK
CORRECTION: Capricor Therapeutics - ForexTV.com
ForexTV.com
CORRECTION: Capricor Therapeutics - GlobeNewswire
GlobeNewswire
CORRECTION: Capricor Therapeutics
GlobeNewswire Inc.
Capricor gains FDA pre-BLA meeting on deramiocel for Duchenne muscular dystrophy - Seeking Alpha
Seeking Alpha
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy - GlobeNewswire
GlobeNewswire
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
GlobeNewswire Inc.
While shareholders of Capricor Therapeutics (NASDAQ:CAPR) are in the black over 5 years, those who bought a week ago aren't so fortunate - Simply Wall St
Simply Wall St
Ratios Uncovered: Breaking Down Capricor Therapeutics Inc (CAPR)'s Trailing Twelve Months Metrics – DWinneX - The Dwinnex
The Dwinnex
Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Large Growth in Short Interest - Defense World
Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Large Growth in Short Interest - MarketBeat
MarketBeat
Capricor: Rolling BLA Submission Of CAP-1002 To Get DMD Treatment Program Going (CAPR) - Seeking Alpha
Seeking Alpha
(CAPR) Technical Pivots with Risk Controls - Stock Traders Daily
Stock Traders Daily
Capricor: Rolling BLA Submission Of CAP-1002 To Get DMD Treatment Program Going (CAPR) - Seeking Alpha
Seeking Alpha
Strength Seen in Capricor (CAPR): Can Its 5.7% Jump Turn into More Strength? - Yahoo Movies UK
Yahoo Movies UK
Pfizer Phase III DMD Gene Therapy Study Misses Goal - Markets Insider
Markets Insider
The Significance of Moving Averages in Capricor Therapeutics Inc Inc. (CAPR) Price Performance - The InvestChronicle
The InvestChronicle
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks Investment Research
Pfizer's Duchenne gene therapy fails in late-stage study - Yahoo News Canada
Yahoo News Canada
Capricor unit enters into amendment to CIRM notice of loan award - Reuters.com
Reuters.com
Potash America (OTCMKTS:PTAM) Stock Price Crosses Above 50 Day Moving Average of $0.00 - Defense World
Defense World
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above Fifty Day Moving Average of $5.70 - Defense World
Defense World
Capricor Therapeutics (NASDAQ:CAPR) Share Price Passes Above 50-Day Moving Average of $5.70 - MarketBeat
MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above Fifty Day Moving Average of $5.70 - Defense World
Defense World
Capricor moves forward with FDA on Duchenne treatment By Investing.com - Investing.com
Investing.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Autonomix Medical (NASDAQ:AMIX), Adlai N - Benzinga
Benzinga
What's Going On With Capricor Therapeutics Stock Tuesday? - Capricor Therapeutics (NASDAQ:CAPR) - Benzinga
Benzinga
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular ... - GlobeNewswire
GlobeNewswire
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular ... - Yahoo Finance
Yahoo Finance
What's Going On With Capricor Therapeutics Stock Tuesday? - Capricor Therapeutics (NASDAQ:CAPR) - Benzinga
Benzinga
Capricor Advances in DMD Therapy With Positive Study Data - Markets Insider
Markets Insider
Capricor (CAPR) Advances in DMD Therapy With Positive Study Data
Zacks Investment Research
Capricor (CAPR) Advances in DMD Therapy With Positive Study Data - Zacks Investment Research
Zacks Investment Research
Capricor (CAPR) Advances in DMD Therapy With Positive Study Data - Yahoo Finance
Yahoo Finance
In DMD, three years of CAP-1002 still showing stabilized arm... - Muscular Dystrophy News
Muscular Dystrophy News
In DMD, three years of CAP-1002 still showing stabilized arm... - Muscular Dystrophy News
Muscular Dystrophy News
Its Stock Has Paid Off Big Time For Capricor Therapeutics Inc – Sete News - SETE News
SETE News
Capricor reports sustained benefits in DMD treatment study - Investing.com India
Investing.com India
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):